Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Peptic ulcer disease

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Haematemesis, melaena with haemodynamic compromise, syncope, sudden severe abdominal pain, rigid peritonism, free gas or persistent vomiting with metabolic disturbance indicates a complicated ulcer. Start the relevant bleeding, perforation or obstruction pathway immediately, keep the patient nil by mouth when surgery or urgent endoscopy is likely, and involve senior gastroenterology or upper-GI surgery. A temporarily normal haemoglobin does not exclude major acute blood loss.

Synopsis

Identify gastric and duodenal ulcer disease, address Helicobacter pylori and ulcerogenic medicines, recognise bleeding, perforation and obstruction early, and prove healing where a gastric lesion could conceal malignancy.

  • Peptic ulcer is a mucosal break extending beyond the muscularis mucosae, most commonly driven by H. pylori infection or exposure to NSAIDs and aspirin.
  • Epigastric pain patterns around meals are not sufficiently accurate to distinguish gastric from duodenal ulcer or to exclude cancer.
  • Ask about prescribed and non-prescribed ibuprofen, naproxen, aspirin and combination remedies; corticosteroids, anticoagulants and antiplatelets amplify bleeding risk in combination.
  • Test for active H. pylori with valid preparation and eradicate confirmed infection using the current resistance-aware regimen, then demonstrate cure when an ulcer was present.
  • Stop the NSAID where possible; if it must continue after healing, reassess indication and dose and co-prescribe appropriate gastroprotection according to risk.
  • Gastric ulcers require adequate biopsy and planned repeat endoscopy, commonly at 6–8 weeks, because benign appearance and symptom improvement do not reliably exclude malignancy.
  • Duodenal ulcers are very rarely malignant, but persistent or recurrent disease still requires confirmation of eradication, medicine review and consideration of hypersecretory or inflammatory causes.
  • Major complications are upper-GI bleeding, free or contained perforation, penetration into an adjacent organ and chronic scarring that produces gastric outlet obstruction.

Key red flags

Acute haemorrhage

Haematemesis, coffee-ground vomit, melaena, postural symptoms or shock requires acute upper-GI bleeding assessment. Bright rectal blood can occur with a brisk proximal bleed.

Perforation or penetration

Abrupt severe pain with guarding suggests free perforation; pain radiating to the back or persistent focal pain may reflect posterior penetration. Both require urgent imaging and surgical review.

Investigation priorities

01
Upper-GI endoscopyFirst step

Confirm ulcer site, describe bleeding stigmata and obtain appropriate tissue.

Management branches

HealTreat an uncomplicated ulcer

Endoscopy demonstrates a peptic ulcer without active major bleeding, perforation or fixed outlet obstruction.

  1. Identify active H. pylori and every ulcerogenic medicine, including over-the-counter NSAIDs, low-dose aspirin, steroids, anticoagulants and antiplatelets, then assess tobacco exposure and cancer features.
  2. Eradicate confirmed H. pylori and prescribe a defined acid-suppression course appropriate to ulcer site and cause; discontinue the offending NSAID where clinically possible.
  3. Arrange proof of eradication and, for a gastric ulcer, repeat endoscopy at the planned healing interval with review of biopsy adequacy and any residual lesion.

Key medicines

Proton-pump inhibitor for ulcer healingA licensed example is omeprazole 20 mg once daily for 4–8 weeks; NICE uses a full-dose PPI for eight weeks in NSAID-associated ulcer, with product and duration adjusted to cause and response.Use a named formulary product and review long-term need. Check interactions, renal and hepatic context, magnesium and B12 risk when prolonged, enteric infection risk and rebound symptoms; PPI use can invalidate H. pylori testing.
H. pylori eradication treatment when infection is confirmedUse the current seven-day NICE and local antimicrobial combination, selected for penicillin allergy and previous antibiotic exposure; do not copy a historical regimen without checking current strengths and resistance advice.Reconcile the full combination, pregnancy, allergy, QT and CYP interactions, renal and liver function and previous macrolide, nitroimidazole or fluoroquinolone use. Persistent symptoms alone do not justify repeated antibiotics.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG184: Dyspepsia and proven peptic ulcerUK recommendations for H. pylori, NSAID withdrawal, acid suppression and gastric ulcer repeat endoscopy.
  • Omeprazole 20 mg capsules SmPCLicensed gastric, duodenal and NSAID-associated ulcer regimens with product contraindications and interactions.
  • BSG and AUGIS upper-GI endoscopy quality standardsNational quality principles for lesion inspection, cancer detection, reporting and follow-up.
  • NICE NG12: Suspected upper-GI cancer referralCurrent alarm-feature combinations that supersede uncomplicated dyspepsia management.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom